These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38517637)
1. Biodistribution and dosimetry of Li H; Pei W; Yang X; Qu G; Hua Q; Liu L; Wang Y; Xu T; Chen Y EJNMMI Res; 2024 Mar; 14(1):30. PubMed ID: 38517637 [TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of 68 Ga- or 177 Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases : A Phase 0/I Study. Qiu L; Wang Y; Liu H; Wang Q; Chen L; Liu L; Wang L; Feng Y; Chen Y Clin Nucl Med; 2023 Jun; 48(6):489-496. PubMed ID: 36976706 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of Safety and Dosimetry of Fernández R; Eppard E; Lehnert W; Jiménez-Franco LD; Soza-Ried C; Ceballos M; Ribbeck J; Kluge A; Rösch F; Meckel M; Zhernosekov K; Kramer V; Amaral H J Nucl Med; 2021 Aug; 62(8):1126-1132. PubMed ID: 33419945 [TBL] [Abstract][Full Text] [Related]
4. Lutetium177-Labeled DOTA-Ibandronate: A Novel Radiopharmaceutical for Targeted Treatment of Bone Metastases. Wang Q; Yang J; Wang Y; Liu H; Feng Y; Qiu L; Chen Y Mol Pharm; 2023 Mar; 20(3):1788-1795. PubMed ID: 36802692 [TBL] [Abstract][Full Text] [Related]
5. Biodistribution and post-therapy dosimetric analysis of [ Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA EJNMMI Res; 2019 Nov; 9(1):102. PubMed ID: 31781962 [TBL] [Abstract][Full Text] [Related]
6. Biodistribution and Internal Dosimetry of 68 Ga-DOTA-IBA PET Imaging for Patients With Bone Metastases. Yang J; Deng J; Fan D; Chen G; Lu Z; Liu H; Mok GSP; Chen Y Clin Nucl Med; 2023 Oct; 48(10):847-852. PubMed ID: 37418288 [TBL] [Abstract][Full Text] [Related]
8. First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [ Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Bal C Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959613 [TBL] [Abstract][Full Text] [Related]
9. Preliminary results of biodistribution and dosimetric analysis of [ Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560 [TBL] [Abstract][Full Text] [Related]
10. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[ Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891 [No Abstract] [Full Text] [Related]
11. Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma. Narwadkar YS; Parghane RV; Sahu S; Lad S; Deep K; Wanage G; Suralkar T; Banerjee S; Gupta S; Basu S; Badwe RA Clin Nucl Med; 2024 Apr; 49(4):e149-e155. PubMed ID: 38350067 [TBL] [Abstract][Full Text] [Related]
12. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108 [TBL] [Abstract][Full Text] [Related]
13. First-in-human study of dosimetry, safety and efficacy for [ Zhao R; Lv J; Li M; Xu S; Liang W; Lin X; Gu D; Zeng G; Jin W; Yan Q; Zhong H; Alexoff D; Ploessl K; Zhu L; Kung HF; Wang X Eur J Nucl Med Mol Imaging; 2024 Oct; ():. PubMed ID: 39419848 [TBL] [Abstract][Full Text] [Related]
14. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion. Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254 [TBL] [Abstract][Full Text] [Related]
16. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602 [TBL] [Abstract][Full Text] [Related]
17. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Wehrmann C; Senftleben S; Zachert C; Müller D; Baum RP Cancer Biother Radiopharm; 2007 Jun; 22(3):406-16. PubMed ID: 17651048 [TBL] [Abstract][Full Text] [Related]
18. An Intrapatient Dosimetry Comparison of Rinscheid A; Gäble A; Wienand G; Pfob C; Dierks A; Kircher M; Trepel M; Weckermann D; Lapa C; Bundschuh RA J Nucl Med; 2023 Dec; 64(12):1918-1924. PubMed ID: 37770108 [TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of Xiang F; Zhang Y; Tan X; Yan Y; Liu H; Ma W; Chen Y Front Oncol; 2024; 14():1428498. PubMed ID: 39144828 [TBL] [Abstract][Full Text] [Related]
20. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma. Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA Clin Nucl Med; 2018 May; 43(5):323-330. PubMed ID: 29485430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]